Accessibility Menu
ResMed logo

ResMed(OTC) RSMDF

Current Price$16.72
Market Cap$24.25BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2011)+512%
5 Year-25%
1 Year-28%
1 Month+3%
ResMed last closing stock price
MetricPriceDate
Last closeUSD 16.722026-07-23
ResMed stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 16.722026-07-16
1 month+2.89%USD 16.252026-06-23
3 month-32.48%USD 24.762026-04-24
Year to date-37.03%USD 26.552025-12-30
1 year-27.7%USD 23.132025-07-23
3 year-21.43%USD 21.282023-07-12
5 year-24.5%USD 22.152021-07-19
Since inception+511.92%USD 2.732011-10-26

ResMed Financials at a Glance

Market Cap

$24.25BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$5.54B

Net Income (TTM)

$1.52B

EPS (TTM)

$1.04

P/E Ratio

16.12

Dividend

$0.24

Beta (Volatility)

-0.92 (Low)

Price

$16.72

Volume

1

Open

$16.74

Previous Close

$16.72

Daily Range

$16.72 - $16.74

52-Week Range

$11.85 - $37.91

Estimated Earnings Date

Aug 6, 2026

RSMDF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About ResMed

ResMed Inc. is a leading global medical technology company specializing in the development, manufacturing, and distribution of medical devices and digital health solutions for the healthcare sector. The company operates primarily in two segments: Sleep and Respiratory Care, and Software as a Service (SaaS).

Products and Services
  • Comprehensive range of products for respiratory disorders
  • Cloud-based informatics software for improved patient outcomes
  • Out-of-hospital software solutions for healthcare providers
Growth Outlook
  • Revenue of $1.43 billion in Q3 2026, showing consistent growth
  • Net income of $398 million in Q3 2026, reflecting strong profitability
  • Operating cash flow of $554 million in Q3 2026, indicating robust cash generation
Financial Highlights
  • Trailing twelve months (TTM) revenue of $5.56 billion, demonstrating solid performance
  • Net profit margin of 27.44% TTM, showcasing effective cost management
  • Dividend yield of 1.23% TTM, providing a return to shareholders
ResMed Inc. has established itself as a key player in the medical technology industry, focusing on innovative solutions for sleep and respiratory care. The company's diverse product offerings and strong financial performance position it well for future growth. Recent quarterly results highlight a significant increase in revenue and net income, underscoring the effectiveness of its business strategies. With a solid cash flow and a commitment to shareholder returns, ResMed Inc. presents an attractive opportunity for potential investors interested in the healthcare sector.
AI Generated • Jul 1, 2026

Industry

Healthcare Equipment and Supplies

Sector

Health Care

Employees

10,600

CEO

Mick Farrell, MBA

Website

www.resmed.com

Headquarters

San Diego, CA 92123, US

RSMDF Financials

Key Financial Metrics (TTM)

Gross Margin

61.69%

Operating Margin

34.28%

Net Income Margin

27.44%

Return on Equity

24.41%

Return on Capital

24.71%

Return on Assets

17.30%

Earnings Yield

6.20%

Dividend Yield

1.44%

Payout Ratio

22.39%

Stock Overview

Market Cap

$24.25BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

1.45B

Volume

1

Avg. Volume

5.10K

Financials (TTM)

Gross Profit

$3.42B

Operating Income

$1.90B

EBITDA

$2.19B

Operating Cash Flow

$1.89B

Capital Expenditure

-$141.76M

Free Cash Flow

$1.75B

Cash & ST Invst.

$1.66B

Total Debt

$843.17M

ResMed Performance Analysis

ResMed annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-06-30USD 3,578,127,415N/A
20232023-06-30USD 4,222,995,27918.0%
20242024-06-30USD 4,685,297,52810.9%
20252025-06-30USD 5,146,329,1189.8%
ResMed sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42025-06-304.4%
Q12025-09-30-0.9%
Q22025-12-316.5%
Q32026-03-310.6%
ResMed annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-06-30USD 0.53N/A
20232023-06-30USD 0.6114.8%
20242024-06-30USD 0.6913.7%
20252025-06-30USD 0.9537.4%
ResMed sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42025-06-304.0%
Q12025-09-30-8.1%
Q22025-12-3113.1%
Q32026-03-311.1%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q3 2026YOY CHG

Revenue

$1.43B

+10.8%

Gross Profit

$890.98M

+16.3%

Gross Margin

62.25%

N/A

Market Cap

$24.25BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$2.29M

N/A

Employees

10,600

N/A

Net Income

$398.73M

+9.2%

EBITDA

$583.63M

+24.3%

Quarterly Fundamentals

Name
Q3 2026YOY CHG

Total Cash

$1.66B

+75.7%

Total Debt

$843.17M

+0.4%

Accounts Receivable

$1.05B

+11.3%

Inventory

$911.88M

+5.7%

Long Term Debt

$554.01M

-30.8%

Short Term Debt

$289.16M

+648.1%

Return on Assets

17.30%

N/A

Return on Invested Capital

25.54%

N/A

Free Cash Flow

$520.48M

-6.2%

Operating Cash Flow

$554.13M

-4.2%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
TRUMYTerumo Corporation
$13.25+1.53%
DSKYFDaiichi Sankyo Company, Limited
$15.95-8.96%
TRUMFTerumo Corporation
$12.76-8.86%
FSNUFFresenius SE & Co. KGaA
$54.35+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
NOKNokia
$9.10-0.06%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.42-0.04%
ONDSOndas
$7.80-0.02%
TAT&T
$24.13+0.05%

Questions About RSMDF

What is the current price of ResMed?

ResMed is trading at $16.72 per share.

What is the 52-week range for ResMed?

Over the past 52 weeks, ResMed has traded between $11.85 and $37.91.

How much debt does ResMed have?

As of the most recent reporting period, ResMed reported total debt of $843.17M.

How much cash does ResMed have on hand?

ResMed reported $1.66B in cash and cash equivalents in its most recent financial results.

What is ResMed’s dividend yield?

ResMed currently has a dividend yield of 1.44%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services